Source comparison
Melanotan-1 SubQ vs IM: Full Comparison
Bioavailability 92–96% (reaches systemic circulation within 60–90 min) 92–96% (identical Cmax and AUC to SubQ) No pharmacokinetic advantage to IM. Absorption profiles are equivalent Needle Length 0.5 inch (12.7mm). Standard insulin syringe 1–1.5 inch (25–38mm)
This comparison does not assign a generated winner or score.
- Bioavailability
- 92–96% (reaches systemic circulation within 60–90 min)
- 92–96% (identical Cmax and AUC to SubQ)
- No pharmacokinetic advantage to IM. Absorption profiles are equivalent
- Needle Length
- 0.5 inch (12.7mm). Standard insulin syringe
- 1–1.5 inch (25–38mm). Requires deeper penetration
- Shorter needles reduce user anxiety and eliminate risk of bone contact
- Injection Pain
- Minimal. Penetrates skin and subcutaneous tissue only
- Moderate to high. Muscle fascia contains more nociceptors than fat
- SubQ consistently scores 1–2/10 pain; IM averages 4–6/10
- Bruising Risk
- Low. Superficial vessels compress easily with post-injection pressure
- High. Deeper muscular vessels bleed into tissue without external compression
- IM bruising occurs in 15–25% of injections vs 3–8% for SubQ
- Injection Site Options
- Abdomen, lateral thigh, posterior upper arm, hip. 8+ rotation sites
- Deltoid, vastus lateralis, ventrogluteal. 4–6 rotation sites
- More rotation options reduce lipohypertrophy and injection fatigue
- Tissue Trauma
- Minimal. No detectable creatine kinase elevation post-injection
- Measurable. CK elevation 24–48 hours indicates muscle microtrauma
- Repeated IM injection can cause chronic muscle inflammation over time